Neurocrine Biosciences
NBIX
#1407
Rank
C$21.98 B
Marketcap
C$218.61
Share price
-1.41%
Change (1 day)
31.89%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): C$9.27

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$9.22. In 2025 the company made an earnings per share (EPS) of C$6.63 an increase over its 2024 EPS that were of C$4.65.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$9.2739.9%
2025C$6.6342.6%
2024C$4.6533.07%
2023C$3.4957.76%
2022C$2.2169.47%
2021C$1.31-78.21%
2020C$5.99990%
2019C$0.5581.82%
2018C$0.30-113.5%
2017C-$2.240.62%
2016C-$2.2357.28%
2015C-$1.4225.61%
2014C-$1.1318.84%
2013C-$0.95-1085.71%
2012C$0.09622

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
C$1.80-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$2.83-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$38.80 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C$1.26-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.79-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$4.81-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
C-$41.10-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.62-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK